Nykode Therapeutics ASA announced updates on its mRNA platform at the Cancer Immunotherapy meeting in Boston. The company highlighted the significant advantages of its innovative APC-targeted neoantigen vaccine, delivered in a mRNA-lipid nanoparticle (LNP) format. This latest study demonstrated that the APC-targeted vaccine consistently achieved a broader and more robust immune response across doses compared to an untargeted neoantigen vaccine.

It also provided superior tumor control and resulted in dramatically improved survival rates in a mouse model of colorectal cancer.